1,3-dibenzylisoquinoline | 95226-65-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 1,3-dibenzylisoquinoline
• 英文别名: 1,3-Dibenzyl-isochinolin；bisbenzylisoquinoline
• CAS: 95226-65-6
• 化学式: C₂₃H₁₉N
• 分子量: 309.411
• InChiKey: BJWWOUUGCAPHOV-UHFFFAOYSA-N

物化性质

• 沸点：
  468.2±14.0 °C(Predicted)
• 密度：
  1.122±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  二苄基甲酮 在 盐酸羟胺 、 copper diacetate 、 sodium acetate 、 potassium carbonate 、 三乙胺 、 2,6-双(4,5-二氢噁唑-2-基)吡啶 作用下， 以 甲醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 29.0h， 生成 1,3-dibenzylisoquinoline
  参考文献：
  名称：

  Copper‐Catalyzed Aza‐Sonogashira Cross‐Coupling To Form Ynimines: Development and Application to the Synthesis of Heterocycles

  摘要：

  AbstractNitrogen‐substituted alkynes, such as ynamines and ynamides, are versatile synthetic building blocks. Ynimines bearing additional nucleophilic and electrophilic centers relative to ynamines and ynamides are expected to have high synthetic potential. However, their chemical reactivity remains unexplored owing mainly to the lack of synthetic accessibility. We report herein a versatile copper‐catalyzed synthesis of ynimines from readily available O‐acetyl ketoximes and terminal alkynes. A wide range of O‐acetyl ketoximes derived from diaryl ketones, aryl alkyl ketones and dialkyl ketones underwent cross‐coupling with a diverse set of terminal alkynes to afford the ynimines in good to excellent yields. An unprecedented [5+1] heteroannulation reaction exploiting the reactivity of the ynimine generated in situ was subsequently developed for the synthesis of medicinally important heterocycles, including isoquinolines, azaindoles, azabenzofurans, azabenzothiophenes and carbolines.

  DOI：

  10.1002/anie.202110901

文献信息

• [EN] COMPOSITIONS AND METHODS FOR MAKING NOSCAPINE AND SYNTHESIS INTERMEDIATES THEREOF<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE FABRICATION DE NOSCAPINE ET D'INTERMÉDIAIRES DE SYNTHÈSE DE CELLE-CI
  申请人：EPIMERON INC

  公开号：WO2015021561A1

  公开（公告）日：2015-02-19

  Methods for the manufacture of the therapeutic chemical compound noscapine and noscapine synthesis intermediates comprising contacting a noscapine pathway precursor selected from a first canadine derivative, a first papaveroxine derivative and narcotine hemiacetal with at least one of the enzymes selected from the group CYP82Y1, CYP82X1, AT1, CYP82X2, OMT, CXE1 and NOS.

  制备治疗化合物诺斯卡平和诺斯卡平合成中间体的方法包括将选自第一类肉桂碱衍生物、第一类罂粟碱衍生物和纳科汀半缩醛的诺斯卡平途径前体与来自CYP82Y1、CYP82X1、AT1、CYP82X2、OMT、CXE1和NOS组中至少一种酶中的至少一种接触。
• [EN] DIHYDRO-SPIRO[INDOLINE-3:1'-ISOQUINOLIN]-2-ONES AND THEIR ANALOGUES AND DERIVATIVES AND METHODS OF TREATING CANCER AND OTHER DISEASES<br/>[FR] DIHYDRO-SPIRO[INDOLINE-3:1'-ISOQUINOLÉIN]-2-ONES ET LEURS ANALOGUES ET DÉRIVÉS ET MÉTHODES DE TRAITEMENT DU CANCER ET D'AUTRES MALADIES
  申请人：THE UNIV OF BUEA

  公开号：WO2020183307A1

  公开（公告）日：2020-09-17

  The present invention is directed to various 3',4'-dihydro-2'H-spiro[indoline-3:1'-isoquinolin]-2-one compounds and methods for treating disease states and/or conditions which are mediated through sphingosine-1-phosphate receptor(s). The present invention is also directed to the use of these compounds as anticancer agents and as modulators of sphingosine-1-phosphate receptor function in the treatment of disease states and/or conditions which are mediated through these receptors. In addition, the invention relates to pharmaceutical compositions comprising one or more of these compounds alone or in combination with other therapeutic agents. The invention is also directed to methods of treatment of cancer and/or conditions that may respond to the modulation of sphingosine-1-phospate receptor function and which employ compounds of the present invention or pharmaceutical compositions comprising one or more of the compounds of this invention.

  本发明涉及各种3',4'-二氢-2'H-螺[吲哚啉-3:1'-异喹啉]-2-酮化合物以及治疗经过鞘氨醇-1-磷酸受体介导的疾病状态和/或病况的方法。本发明还涉及将这些化合物用作抗癌剂以及在治疗经过这些受体介导的疾病状态和/或病况中调节鞘氨醇-1-磷酸受体功能。此外，本发明涉及包含这些化合物中的一个或多个的药物组合物，单独或与其他治疗剂联合使用。本发明还涉及治疗癌症和/或可能对鞘氨醇-1-磷酸受体功能调节产生反应的病况的方法，该方法使用本发明的化合物或包含本发明中的一个或多个化合物的药物组合物。
• FATTY ACID DERIVATIVES
  申请人：——

  公开号：US20010006962A1

  公开（公告）日：2001-07-05

  The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH 2 O—, RCH 2 NH—, —COOCH 2 R, —CONHCH 2 R and —SCH 2 R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.

  生物活性化合物（例如药物和农药）的性质，其中分子结构中包含来自醇、醚、苯基、氨基、酰胺、硫醇、羧酸和羧酸酯基团中的一个或多个官能团，通过用来自以下公式的亲脂基团替换其中一个或多个这些官能团来进行修改：RCOO—、RCONH—、RCOS—、RCH2O—、RCH2NH—、—COOCH2R、—CONHCH2R和—SCH2R，其中R是从顺式-8-十七碳烯基、反式-8-十七碳烯基、顺式-10-十九碳烯基和反式-10-十九碳烯基中选择的亲脂基团。
• Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation
  申请人：Tanahashi Takao

  公开号：US20060030586A1

  公开（公告）日：2006-02-09

  A method for preventing and/or alleviating a psychiatric disorder, and/or effectuating sedation, comprising administering a benzylisoquinoline derivative represented by General Formula (I): wherein R 1 , R 2 , R 3 and X each represent a particular group; a method for preventing and/or alleviating a particular symptom, comprising administering a bisbenzylisoquinoline derivative represented by General Formula (II): wherein R 7 , R 8 , R 9 , R 10 and R 11 each represent a particular group, and a health food containing said derivative represented by General Formula (I) or (II).

  一种预防和/或缓解精神障碍，和/或实现镇静的方法，包括给予由通用式(I)表示的苯基异喹啉衍生物，其中R1、R2、R3和X分别代表特定基团；一种预防和/或缓解特定症状的方法，包括给予由通用式(II)表示的双苯基异喹啉衍生物，其中R7、R8、R9、R10和R11各自代表特定基团，以及含有所述通用式(I)或(II)所代表的衍生物的保健食品。
• SALT DERIVATIVE OF TETRAHYDROISOQUINOLINE AND CRYSTALLINE THEREOF AND PREPARATION METHOD THEREFORE AND APPLICATION THEREOF
  申请人：CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY

  公开号：US20190177277A1

  公开（公告）日：2019-06-13

  The present invention discloses a salt derivative of 1-(3-methanesulfonamidobenzyl)-6-methoxy-7-benzyloxy-1,2,3,4-tetrahydroisoquinoline. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL.

  本发明公开了1-(3-甲磺胺基苄基)-6-甲氧基-7-苄氧基-1,2,3,4-四氢异喹啉的盐衍生物。该盐衍生物在水中的溶解度不低于3.0 nmol/mL或1.8 mg/mL。